SEARCH

SEARCH BY CITATION

References

  • 1
    Ricciatti-Sibbald D, Sibbald RG. Dermatologic vehicles. Clin Dermatol 1989; 7: 1124.
  • 2
    Housman TS et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002; 70: 327332.
  • 3
    Tamarkin D et al. Emollient foam in topical drug delivery. Expert Opin Drug Deliv 2006; 3: 799807.
  • 4
    Cash K, Quigley MO. The vehicle found in ketoconazole foam 2% is preferred by patients with mild to severe seborrheic dermatitis over other vehicles, regardless of gender, age, or ethnicity. J Am Acad Dermatol 2008; 58: AB92.
  • 5
    Gottlieb AB et al. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003; 7: 185192.
  • 6
    Kahanek N et al. Desonide: a review of formulations, efficacy and safety. Expert Opin Investig Drugs 2008; 17: 10971104.
  • 7
    Hebert AA. Desonide foam 0.05%: safety in children as young as 3 months. J Am Acad Dermatol 2008; 59: 334340.
  • 8
    Kimball AB et al. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol 2008; 59: 448454.
  • 9
    Stein LF et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5: 303307.
  • 10
    Shalita AR et al. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol 2005; 4: 4856.
  • 11
    Frangos JE, Kimball AB. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses. Expert Opin Pharmacother 2008; 9: 20012007.
  • 12
    Lebwohl M et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41: 269274.
  • 13
    Huang X et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005; 53: S26S38.
  • 14
    Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 2005; 53: S39S49.
  • 15
    Mazzotta A et al. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatol Treat 2007; 18: 8487.
  • 16
    Franz TJ et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628632.
  • 17
    Andreassi L et al. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol 2003; 148: 134138.
  • 18
    Mancuso G et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol 2003; 42: 572575.
  • 19
    Milani M et al. Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curr Med Res Opin 2003; 19: 342345.
  • 20
    Olsen EA et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007; 57: 767774.
  • 21
    Goldstein J, Gurge R. The treatment of hyperkeratosis with a new, 30% urea emollient foam: a series of case studies. J Am Acad Dermatol 2008; 58: AB41.
  • 22
    WeaireD, HutzlerS, eds. The Physics of Foams. Oxford : Oxford University Press, 2001: 118.
  • 23
    Purdon CH et al. Foam drug delivery in dermatology: beyond the scalp. Am J Drug Deliv 2003; 1: 7175.
  • 24
    SandersPA eds. Handbook of Aerosol Technology, 2nd edn. New York : Van Nostrand Reinhold Company, 1979: 299309.
  • 25
    Anon. Summary of control measures under the Montreal Protocol. In: Handbook for the Montreal Protocol on Substances That Deplete the Ozone Layer, 7th edn. 2006: 2740.
  • 26
    Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm 1999; 186: 1330.
  • 27
    McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers – into the new millennium. Int J Pharm 2000; 201: 89107.
  • 28
    Wright P. Polymers for the colloidal stabilization of drugs in HFAs. RDD IV 2006; 1: 243248.
  • 29
    Ridder KB et al. Surfactant solubility and aggregate orientation in hydrofluoroalkanes. Int J Pharm 2005; 295: 5765.
  • 30
    Solvay Fluor. Solkane® 227 pharma and 134a pharma – properties 2006
  • 31
    Murray BS, Ettelaie R. Foam stability: proteins and nanoparticles. Curr Opin Colloid Interface Sci 2004; 9: 314320.
  • 32
    Tamarkin D et al. Oleaginous pharmaceutical and cosmetic foam. US Patent Appl 20070292461 (2007)
  • 33
    Wai-Chiu S et al. Pharmaceutical composition. US Patent 6946120 (2005)
  • 34
    Tamarkin D et al. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof. US Patent Appl 20080069779 (2008)
  • 35
    Tamarkin D et al. Sensation modifying topical composition foam. US Patent Appl 20080253973 (2008)
  • 36
    Pilpel N. Foams in pharmacy. Endeavour 1985; 9: 8791.
  • 37
    SchrammLL eds. Emulsions, Foams, and Suspensions: Fundamentals and Applications, 1st edn. Weinheim : Wiley-VCH. 2005: 201223.
  • 38
    Purewal TS, Grant DJW. Metered Dose Inhaler Technology. Buffalo Grove : Interpharm Press. 1998: 9799.
  • 39
    Zhao Y et al. Engineering novel topical foams using hydrofluroalkane emulsions stabilised with pluronic surfactants. Eur J Pharm Sci 2009; 37: 370377.
  • 40
    Wilson AJ. Experimental techniques for the characterization of foams. In Prud'hommeRK, KhanSA, eds. Foams: Theory, Measurement and Applications, 1st edn. New York : CRC Press. 1995: 243274.
  • 41
    Stone HA et al. Perspectives on foam drainage and the influence of interfacial rheology. J Phys Condens Matter 2003; 15: S283S290.
  • 42
    Langevin D. Aqueous foams: A field of investigation at the frontier between chemistry and physics. Chemphyschem 2008; 9: 510522.
  • 43
    Abram AZ, Hunt BT. Pharmaceutical foam. US Patent 7374747 (2008)
  • 44
    WeaireD, HutzlerS eds. The Physics of Foams. Oxford : Oxford University Press. 2001: 5675.
  • 45
    Kealy T et al. The rheological properties of pharmaceutical foam: implications for use. Int J Pharm 2008; 355: 6780.
  • 46
    Peguin RPS et al. Microscopic and thermodynamic properties of the HFA134a-water interface: atomistic computer simulations and tensiometry under pressure. Langmuir 2006; 22: 88268830.
  • 47
    Selvam P et al. Surfactant design for the 1,1,1,2-tetrafluoroethane-water interface: ab initio calculations and in situ high-pressure tensiometry. Langmuir 2006; 22: 86758683.
  • 48
    Chokshi U et al. Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles. Int J Pharm 2009; 369: 176184.
  • 49
    Feldman SR et al. Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. J Am Acad Dermatol 2000; 42: 10171020.
  • 50
    Huang X et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005; 53: S26S38.
  • 51
    Jones JI et al. Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition. US Patent 6126920 (2000)
  • 52
    Abram AZ, Goldstein L. Fatty acid pharmaceutical foam. US Patent Appl 20080015271 (2008)
  • 53
    Abram AZ. Mousse composition. US Patent 7029659 (2006)
  • 54
    Abram AZ. Mousse composition. USA Patent 6730288 (2004)
  • 55
    Huggins JK, Houlden RJ. Film foaming hydroalcoholic foam. US Patent Appl 20060233727 (2006)
  • 56
    Zhao Y et al. A dynamic topical hydrofluoroalkane foam to induce nanoparticle modification and drug release in situ. Eur J Pharm Biopharm 2009; 72: 521528.
  • 57
    Brown MA, Jones SA. Topical formulations. US Patent Appl 20090191271 (2009)